Comparison of 18F-DCFPyL and 68Ga-PSMA-11 PET-CT for eligibility screening for 177Lu-PSMA-617 therapy in metastatic castrate resistant prostate cancer: Should insurers consider these methods equivalent?

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

You are going to email the following Comparison of 18F-DCFPyL and 68Ga-PSMA-11 PET-CT for eligibility screening for 177Lu-PSMA-617 therapy in metastatic castrate resistant prostate cancer: Should insurers consider these methods equivalent?

Message Subject (Your Name) has sent you a message from Journal of Nuclear Medicine

Message Body (Your Name) thought you would like to see the Journal of Nuclear Medicine web site.